PT2385 treatment inhibited the expression of HIF2α target genes in ccRCC cell lines and tumour xenografts and it promoted tumour regression faster than sunitinib [19], as did PT2399 [20]. Here, EPAS1 is linked to nonpapillary renal cell carcinoma.